Status:
COMPLETED
Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults
Lead Sponsor:
HIV Vaccine Trials Network
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
EuroVacc Foundation
Conditions:
HIV Infections
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
Investigators will examine the safety of and immune responses to two vaccines expressing synthetic HIV proteins: NYVAC-B (a poxvirus), and rAd5 (an adenovirus). The study will compare responses in par...
Detailed Description
In order to halt the HIV pandemic an effective vaccine must be developed. In this study, investigators will examine the safety and immune response to a prime-boost strategy using two different vaccine...
Eligibility Criteria
Inclusion
- Willing and able to provide informed consent
- Assessment of understanding, including understanding of the Step Study results
- Willingness to receive HIV test results
- Amenable to HIV risk reduction counseling, committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit
- Assessed by clinic staff as being "low risk" for HIV infection on the basis of sexual behaviors within the 12 months prior to enrollment. More information on this criterion is in the study protocol.
- Good general health
- Neutralizing antibody titers of Ad5 less than 1:18
- Hemoglobin count of 11.0 g/dL or more for female volunteers, and 13.0 g/dL or more for male volunteers
- White blood cell count of 3300 to 12000 cells/mm\^3
- Total lymphocyte count of 800 cells/mm\^3 or more
- Remaining differential either within institutional normal range or with site physician approval
- Platelets in the range of 125,000 to 550,000/mm\^3
- Chemistry panel: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and creatinine values less than or equal to the institutional upper limits of normal
- HIV-uninfected
- Negative Hepatitis B surface antigen (HBsAg)
- Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive
- Normal urine
- Not pregnant
- A volunteer who was born female must agree to consistently use effective contraception from at least 21 days prior to enrollment through the last protocol visit for sexual activity that could lead to pregnancy
Exclusion
- Excessive alcohol use or chronic marijuana use, or any other illicit drug use within the 12 months prior to enrollment
- History of newly acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus type 2, chlamydia, pelvic inflammatory disease, trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid, within the 12 months prior to enrollment
- HIV vaccine received in a prior HIV vaccine trial. For potential participants who have received control/placebo in an HIV vaccine trial, documentation of the identity of the study control/placebo must be provided to the HVTN 078 PSRT, who will determine eligibility on a case-by-case basis.
- Immunosuppressive medications received within 168 days before first vaccination
- Blood products received within 120 days before first vaccination
- Immunoglobulin received within 60 days before first vaccination
- Live attenuated vaccines received within 30 days before first vaccination or scheduled within 14 days after first injection
- Any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination
- Allergy treatment with antigen injections within 30 days before first vaccination or that are scheduled within 14 days after first vaccination
- Investigational research agents received within 30 days before first vaccination
- Intent to participate in another study of an investigational research agent during the planned duration of the HVTN 078 study
- Current anti-tuberculosis (TB) prophylaxis or therapy
- Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. More information on this criterion is in the study protocol.
- Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participant's ability to give informed consent
- Serious adverse reactions to vaccines including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain
- Active syphilis infection
- Allergy to eggs and/or egg products
- History of, or known active cardiac disease
- Participants who have 2 or more specified cardiac risk factors as defined by the study. More information on this criterion is in the study protocol.
- ECG with clinically significant findings. More information on this criterion is in the study protocol.
- Autoimmune disease
- Immunodeficiency
- Asthma other than mild, well-controlled asthma.
- Diabetes mellitus type 1 or type 2, including cases controlled with diet alone
- Thyroidectomy, or thyroid disease
- Angioedema
- Hypertension
- Body mass index (BMI) equal to 40 and above or 35 and above with at least two of the following: systolic blood pressure greater than 140 mm Hg, diastolic blood pressure more than 90 mm Hg, current smoker, known hyperlipidemia
- Bleeding disorder
- Malignancy
- Seizure disorder
- Asplenia
- Psychiatric condition that precludes compliance with the protocol
- Pregnant or breastfeeding
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00961883
Start Date
August 1 2009
Last Update
September 6 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
BH10/513
Lausanne, Switzerland, 1011
2
BT06/614
Lausanne, Switzerland, 1011